Suppr超能文献

≥75 岁伴有卒中史的日本老年非瓣膜性心房颤动患者的基线特征 - ANAFIE 登记研究。

Baseline Characteristics of Elderly Japanese Patients Aged ≥75 Years With Non-Valvular Atrial Fibrillation and a History of Stroke - ANAFIE Registry.

机构信息

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.

Department of Neurology, National Cerebral and Cardiovascular Center.

出版信息

Circ J. 2020 Feb 25;84(3):516-523. doi: 10.1253/circj.CJ-19-0974. Epub 2020 Jan 25.

Abstract

BACKGROUND

Despite the well-established benefits in patients with non-valvular atrial fibrillation (NVAF), oral anticoagulants (OAC) have been underused in elderly patients. We investigated the characteristics and status of anti-thrombotic therapy in elderly NVAF patients in Japan according to a history of stroke or of transient ischemic attack (TIA).

METHODS AND RESULTS

In a multicenter, prospective, observational study, 32,726 Japanese patients aged ≥75 years with NVAF were enrolled, and divided into 3 groups for the present analysis: 6,543 patients with previous ischemic stroke (IS) or TIA (2,410 women), 275 with previous hemorrhagic stroke (HS; 113 women), and the other 25,908 without previous stroke or TIA (11,470 women). Median CHADSscore was 5 in patients with IS/TIA, 2 in those with HS and 2 in those without stroke/TIA (P<0.05). Anti-thrombotic agents were used in 97.1% of patients with IS/TIA (OAC alone in 73.0%; antiplatelets alone in 3.7%; and both in 23.4%), 90.2% of those with HS (84.7%, 3.2%, and 12.1%, respectively), and 94.1% of those without stroke/TIA (83.4%, 2.7%, and 13.9%, respectively; P<0.05 for any anti-thrombotic choice). Of patients taking OAC, 72.2% received direct OAC (DOAC).

CONCLUSIONS

In this unique nationwide NVAF registry of >30,000 elderly patients, >90% of patients, even those with HS, received anti-thrombotic therapy, nearly always with OAC. DOAC were the major choice of OAC.

摘要

背景

尽管在非瓣膜性心房颤动(NVAF)患者中已确立了口服抗凝剂(OAC)的益处,但在老年患者中,OAC 的使用仍不足。我们根据中风或短暂性脑缺血发作(TIA)的病史,研究了日本老年 NVAF 患者的抗血栓治疗特点和现状。

方法和结果

在一项多中心、前瞻性、观察性研究中,纳入了 32726 名年龄≥75 岁的 NVAF 日本患者,并分为 3 组进行本次分析:6543 名有既往缺血性中风(IS)或 TIA(2410 名女性),275 名有既往出血性中风(HS;113 名女性),其他 25908 名无既往中风或 TIA(11470 名女性)。IS/TIA 患者的中位 CHADS 评分 5 分,HS 患者为 2 分,无中风/TIA 患者为 2 分(P<0.05)。IS/TIA 患者中 97.1%(OAC 单独治疗 73.0%;抗血小板单独治疗 3.7%;两者联合治疗 23.4%)、HS 患者中 90.2%(分别为 84.7%、3.2%和 12.1%)、无中风/TIA 患者中 94.1%(分别为 83.4%、2.7%和 13.9%)使用了抗血栓药物(P<0.05)。服用 OAC 的患者中,72.2%接受了直接 OAC(DOAC)治疗。

结论

在这项针对超过 30000 名老年 NVAF 患者的独特的全国性 NVAF 登记研究中,超过 90%的患者,甚至是 HS 患者,都接受了抗血栓治疗,几乎总是使用 OAC。DOAC 是 OAC 的主要选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验